The National Institute for Health and Care Excellence (NICE) has now recommended that Tecentriq (atezolizumab) from Roche may be used within...
The FDA has restricted use of Keytruda (pembrolizumab) from Merck Inc.and Tecentriq (atezolizumab) from Roche among patients with locally advanced...
Genentech/Roche announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq (atezolizumab) met its co-primary endpoints.
Genentech announced data from the positive, pivotal Phase III OAK study of Tecentriq (atezolizumab) which showed Tecentriq helped people live...
Genentech, announced positive results from the Phase III IMpassion130 study of Tecentriq (atezolizumab) plus chemotherapy (Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) for...
Roche announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval...
Hoffmann-La Roche Limited announced that Health Canada has granted market authorization for Tecentriq (atezolizumab for injection), in combination with Avastin (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.
Genentech, announced that the Phase III IMvigor211 study that evaluated Tecentriq (atezolizumab) in people with locally advanced or metastatic urothelial...
Genentech, a member of the Roche Group announced that the Phase III IMagyn050 study showed that the addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly-diagnosed advanced-stage ovarian cancer.